Merck licenced xevinapant from Debiopharm International in 2021 in a deal worth $1.08bn. Image Credit: Anne Czichos / Shutterstock Merck KGaA (Merck) has discontinued the
Trying to figure out whether someone has Alzheimer’s disease usually involves a battery of assessments-;interviews, brain imaging, blood and cerebrospinal fluid tests.
Awareness of the harms to patients caused by errors in diagnosis and treatment has been front and center for nearly 25 years. A different kind
A genetic variation common in people of African ancestry is associated with an increased risk of complications from diabetes, including diabetic retinopathy, according to a
New research from Edith Cowan University (ECU) has found that nitrate from plant sources is associated with a lower risk of mortality while nitrate from
Heather Bassett, M.D., Chief Medical Officer with Xsolis The year 2023 marked a milestone for generative AI, bringing unprecedented attention to the immense potential of AI
The global health toll of alcohol remains “unacceptably high” across the globe, the World Health Organization said this week. Despite alcohol’s immense health toll, however,
Pharmaceutical companies in the U.K. have increasingly violated a voluntary industry marketing code but complaints are also taking longer to review, according to a new
The TDR Three Key Takeaways regarding MindBio Therapeutics and MB22001 Early trials indicate MB22001 could offer an alternative to traditional antidepressants Hanka stresses MB22001’s impact
A Phase IIb trial is assessing the safety and efficacy of the asset in patients with ovarian cancer-derived peritoneal metastases. Credit: Tattoboo/ Shutterstock. Oncoinvent has